Instruction for use: Gelplastan

Dosage form: Hemostatic powder for topical application

ATX

B02BC01 Gelatin absorbent sponge

Pharmacological group

Hemostatic agent for topical application [Coagulants (including factors of blood coagulation), hemostatics in combinations]

The nosological classification (ICD-10)

R58 Bleeding, not elsewhere classified: Abdominal apoplexy; Hemorrhagia; Haemorrhage of the esophagus; Hemorrhage; Generalized bleeding; Diffuse bleeding; Diffuse bleeding; Prolonged bleeding; Blood loss; Blood loss during surgical interventions; Bleeding during surgery and in the postoperative period; Bleeding during labor; Bleeding and haemorrhage in hemophilia B; Bleeding from the gums; Bleeding intraoperative abdominal; Bleeding against a background of coumarin anticoagulants; Hepatic hepatitis; Bleeding in hemophilia A; Bleeding at hemophilia A; Bleeding with inhibitory forms of hemophilia A and B; Bleeding due to leukemia; Bleeding in patients with leukemia; Bleeding; Bleeding due to portal hypertension; Bleeding due to hyperfibrinolysis; Drug bleeding; Local bleeding; Local bleeding due to activation of fibrinolysis; Massive blood loss; Acute blood loss; Parenchymal hemorrhage; Hepatic bleeding; Postoperative hemorrhage; Kidney bleeding; Vascular-platelet hemostasis; Traumatic bleeding; Threatening bleeding; Chronic blood loss

T14.1 Open wound of unspecified body region: Secondary healing processes; Sluggishly granulating wounds; Sluggishly healing wounds; Sluggish wounds; Deep Wounds; Purulent wound; Granulating wounds; Prolonged non-healing wound; Long-lasting non-healing wound and ulcer; Long-lasting non-healing soft tissue wound; Healing of wounds; Wound healing; Capillary bleeding from superficial wounds; Bleeding wound; Radiation Wounds; Slowly epithelializing wounds; Minor cuts; Suppurated wounds; Violation of wound healing processes; Breach of skin integrity; Violations of the integrity of the skin; Violations of the integrity of the skin; Small cuts; Uninfected wounds; Uncomplicated wounds; Operating wound; Primary treatment of surface contaminated wounds; Primary wound treatment; Primary-delayed treatment of wounds; Poorly cicatrizing wound; Poor wound healing; Bad wound; Superficial injury; Superficial wound with mild exudation; Wound; The wound is large; Bite wound; Wound process; Wounds; Wound healing wounds; Stump Wounds; Wounds for gunshot; Wounds with deep cavities; Difficult healing wounds; Difficult wounds; Chronic Wounds

Composition

Powder for topical use 1 fl.

Active substances: Blood plasma of bovine 0.175 / 0.35 g

Kanamycin monosulfate 0.075 / 0.15 g

Gelatin food up to 2.5 / up to 5 grams

Description of dosage form

Amorphous-crystalline powder from yellow to dark yellow with a specific odor.

Pharmachologic effect

Mode of action - Hemostatic.

Pharmacodynamics

Gelplastan is an absorbent hemostatic agent for topical application. The drug accelerates the process of thrombosis at the site of application, has antibacterial activity, is absorbed in the tissues of the body.

Indication of the drug Gelplastan

To achieve hemostasis and "gluing" of tissues, especially with extensive damages of the parenchymal organs (for example, the liver, spleen, kidneys), as well as with open musculoskeletal injuries.

Contraindications

Hypersensitivity to the components of the drug;

Congenital and acquired disorders of the blood coagulation system;

Children's age (<18 years).

Side effects

Allergic reactions.

Interaction

Not found.

Dosing and Administration

Locally.

The bottle with the drug is opened immediately before use. Immediately after drainage of the bleeding wound surface, the powder is applied evenly and pressed with a gauze cloth until the bleeding stops completely.

If the thickness of the powder layer is insufficient, the surface may be incurvated blood. In this case, you should raise the gauze pad and add additional amount of the drug to the bleeding sites and then squeeze again. After the final stop of bleeding, excess drug is removed.

The dose of the drug depends on the intensity of bleeding and the area of the wound surface. The maximum consumption of the drug per patient usually does not exceed 15 g, but it can be used in a larger dose.

Overdose

There are no reports of overdose cases. Since the content of active components is very small, cases of overdose with Gelpastan are virtually impossible.

Special instructions

Gelplastan is available in sterile bottles. Only undisturbed packages should be used. Re-sterilization is not possible.

The production of the drug uses raw materials from animals that have no bacterial, mycoplasmal, prion, and viral etiology, pathogenic to humans.

Do not use drugs that reduce blood clotting, while using Gelplastan.

Release form

Powder for topical application. For 2.5 and 5 g in sterile bottles of neutral glass with a capacity of 5 and 10 ml, corked with rubber stoppers and rolled with aluminum caps, in individual sterile packs each. For 10 fl. Placed in a cardboard box; The packs are placed in a group package.

Manufacturer

OOO NPO Tanais. 109382, Moscow

Place of production: FSUE "Shchelkovsky biocomplex". 141142, Moscow region

OOO NPO "Tanais" produces the drug on behalf of the LLC NPO "TANAIS PHARMA".

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Gelplastan

In dry, the dark place at a temperature of no higher than 25 ° C

Keep out of the reach of children.

Shelf life of the drug Gelplastan

3 years.

Do not use after the expiry date printed on the package.